HER2 Support Group Forums - View Single Post

Christine MH-UK · 03-17-2006, 03:58 PM

Hi unregistered,

The FinHer results do look good, but the problem is that there is a wide confidence interval, which means that although the group studed had a 50% reduction in recurrence, the estimation for what the benefit would be in a really large group ranges from the mid 20s to almost 80 percent. As such, it is difficult to compare it directly with the other much larger trials, although it seems statistically unlikely that it would be worse than them.

The great thing about FinHer is the lack of any heart problems and giving the herceptin-based chemo first only seems logical. There are some women, after all, who never get herceptin because their hearts are too damaged by their prior treatment with adriamycin and that needs to be factored in when comparing the trials.

If the short course proves to be as successful, I'm all for it being adopted. I am half way through a year of herceptin and am really fed up of being a patient.

At present, it does seem like FinHer is best at the very least in cases where the other treatments would pose too much risk to the heart.

03-17-2006, 03:58 PM	#6
Christine MH-UK Senior Member Join Date: Sep 2005 Posts: 414	What is unknown about FinHer Hi unregistered, The FinHer results do look good, but the problem is that there is a wide confidence interval, which means that although the group studed had a 50% reduction in recurrence, the estimation for what the benefit would be in a really large group ranges from the mid 20s to almost 80 percent. As such, it is difficult to compare it directly with the other much larger trials, although it seems statistically unlikely that it would be worse than them. The great thing about FinHer is the lack of any heart problems and giving the herceptin-based chemo first only seems logical. There are some women, after all, who never get herceptin because their hearts are too damaged by their prior treatment with adriamycin and that needs to be factored in when comparing the trials. If the short course proves to be as successful, I'm all for it being adopted. I am half way through a year of herceptin and am really fed up of being a patient. At present, it does seem like FinHer is best at the very least in cases where the other treatments would pose too much risk to the heart.